Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers (Nature, (2018), 554, 7691, (189-194), 10.1038/nature25475);HER kinase inhibition in patients with HER2-and HER3-mutant cancers

Nature

Volumn 554, Issue 7691, 2018, Pages 189-194

  Hyman, David M ^a   Piha Paul, Sarina A ^b   Won, Helen ^a   Rodon, Jordi ^c   Saura, Cristina ^c   Shapiro, Geoffrey I ^d   Juric, Dejan ^e   Quinn, David I ^f   Moreno, Victor ^g   Doger, Bernard ^g   Mayer, Ingrid A ^h   Boni, Valentina ⁱ   Calvo, Emiliano ⁱ   Loi, Sherene ^j   Lockhart, Albert C ^k   Erinjeri, Joseph P ^a   Scaltriti, Maurizio ^a   Ulaner, Gary A ^a   Patel, Juber ^a   Tang, Jiabin ^a   Beer, Hannah ^a   Duygu Selcuklu, S ^a   Hanrahan, Aphrothiti J ^a   Bouvier, Nancy ^a   Melcer, Myra ^a   Murali, Rajmohan ^a   Schram, Alison M ^a   Smyth, Lillian M ^a   Jhaveri, Komal ^a   Li, Bob T ^a   Drilon, Alexander ^a   Harding, James J ^a   Iyer, Gopa ^a   Taylor, Barry S ^a   Berger, Michael F ^a   Cutler, Richard E ^l   Xu, Feng ^l   Butturini, Anna ^l   Eli, Lisa D ^l   Mann, Grace ^l   Farrell, Cynthia ^l   Lalani, Alshad S ^l   Bryce, Richard P ^l   Arteaga, Carlos L ^h   Meric Bernstam, Funda ^b   Baselga, José ^a   Solit, David B ^a   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e Massachusetts General Cancer Center   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^h VANDERBILT INGRAM CANCER CENTER   (United States)

ⁱ START   (Spain)

^j PETER MACCALLUM CANCER CENTRE   (Australia)

^k WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l Puma Biotechnology Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; NERATINIB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; ERBB3 PROTEIN, HUMAN; N-(4-(3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO)-3-CYANO-7-ETHOXY-6-QUINOLYL)-4-(DIMETHYLAMINO)-2-BUTENAMIDE; PROTEIN KINASE INHIBITOR; QUINOLINE DERIVATIVE;

ALLELE; CANCER; ENZYME; GENOME; HISTOLOGY; INHIBITION; INHIBITOR; MUTATION;

ADULT; AGED; ARTICLE; BILIARY TRACT CANCER; BLADDER CANCER; BREAST CANCER; COLORECTAL CANCER; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; FEMALE; GENE MUTATION; GENOMICS; HER3 GENE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; NON SMALL CELL LUNG CANCER; ONCOGENE NEU; OVARY CANCER; PAGET SKIN DISEASE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SALIVARY GLAND CANCER; SMALL INTESTINE CANCER; STOMACH CANCER; UTERINE CERVIX CANCER; VAGINA CANCER; ALLELE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CLINICAL TRIAL; COHORT ANALYSIS; ENZYMOLOGY; GENETICS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MUTATION; NEOPLASM; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTINEOPLASTIC AGENTS; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; MUTATION, MISSENSE; NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINOLINES; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; TREATMENT OUTCOME;

EID: 85041717285     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/s41586-019-0974-0     Document Type: Erratum

References (49)

1. Chmielecki, J. et al. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin. Oncologist 20, 7-12 (2015).
2. Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10, 000 patients. Nat. Med. 23, 703-713 (2017).
3. Schram, A. et al. Landscape of somatic ERBB2 mutations: Findings from AACR GENIE and comparison to ongoing ERBB2 mutant basket study. Cancer Res. 77, Abstract LB-103 (2017).
4. Chang, M. T. et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specifcity. Nat. Biotechnol. 34, 155-163 (2016).
5. Bose, R. et al. Activating HER2 mutations in HER2 gene amplifcation negative breast cancer. Cancer Discov. 3, 224-237 (2013).
6. Kavuri, S. M. et al. HER2 activating mutations are targets for colorectal cancer treatment. Cancer Discov. 5, 832-841 (2015).
7. Jaiswal, B. S. et al. Oncogenic ERBB3 mutations in human cancers. Cancer Cell 23, 603-617 (2013).
8. Chumsri, S. et al. Prolonged response to trastuzumab in a patient with HER2-nonamplifed breast cancer with elevated HER2 dimerization harboring an ERBB2 S310F mutation. J. Natl. Compr. Canc. Netw. 13, 1066-1070 (2015).
9. Zabransky, D. J. et al. HER2 missense mutations have distinct efects on oncogenic signaling and migration. Proc. Natl Acad. Sci. USA 112, E6205-E6214 (2015).
10. Hyman, D. M. et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N. Engl. J. Med. 373, 726-736 (2015).
11. Hyman, D. M. et al. AKT inhibition in solid tumors with AKT1 mutations. J. Clin. Oncol. 35, 2251-2259 (2017).
12. Ross, J. S. et al. A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma. Clin. Cancer Res. 20, 68-75 (2014).
13. Ross, J. S. et al. Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations. Clin. Cancer Res. 19, 2668-2676 (2013).
14. Wolf, A. C. et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J. Clin. Oncol. 31, 3997-4013 (2013).
15. Ma, C. X. et al. Neratinib efcacy and circulating tumor DNA detection of HER2 mutations in HER2 non-amplifed metastatic breast cancer. Clin. Cancer Res. 23, 5687-5695 (2017).
16. Yasuda, H. et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci. Transl. Med. 5, 216ra177 (2013).
17. Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627-1639 (2015).
18. Kosaka, T. et al. Response heterogeneity of EGFR and HER2 exon 20 insertions to covalent EGFR and HER2 inhibitors. Cancer Res. 77, 2712-2721 (2017).
19. Freedman, R. A. et al. Translational Breast Cancer Research Consortium (TBCRC) 022: a phase II trial of neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J. Clin. Oncol. 34, 945-952 (2016).
20. Shi, W. et al. Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. Ann. Oncol. 28, 128-135 (2017).
21. Loibl, S. et al. PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from fve prospective trials investigating lapatinib and trastuzumab. Ann. Oncol. 27, 1519-1525 (2016).
22. Baselga, J. et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, frst-line metastatic breast cancer. J. Clin. Oncol. 32, 3753-3761 (2014).
23. Schram, A. M., Berger, M. F. & Hyman, D. M. Precision oncology: charting a path forward to broader deployment of genomic profling. PLoS Med. 14, e1002242 (2017).
24. Hyman, D. M., Taylor, B. S. & Baselga, J. Implementing genome-driven oncology. Cell 168, 584-599 (2017).
25. Jordan, E. J. et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efcient patient matching to approved and emerging therapies. Cancer Discov. 7, 596-609 (2017).
26. Baselga, J. et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14, 737-744 (1996).
27. Vogel, C. L. et al. Efcacy and safety of trastuzumab as a single agent in frst-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719-726 (2002).
28. Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
29. Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687-697 (2010).
30. Swain, S. M. et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N. Engl. J. Med. 372, 724-734 (2015).
31. Blackwell, K. L. et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J. Clin. Oncol. 28, 1124-1130 (2010).
32. Baselga, J. et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379, 633-640 (2012).
33. Bertotti, A. et al. A molecularly annotated platform of patient-derived xenografts ('xenopatients') identifes HER2 as an efective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 1, 508-523 (2011).
34. Sartore-Bianchi, A. et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 17, 738-746 (2016).
35. Kaufman, B. et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J. Clin. Oncol. 33, 244-250 (2015).
36. Le, D. T. et al. Mismatch repair defciency predicts response of solid tumors to PD-1 blockade. Science 357, 409-413 (2017).
37. Hyman, D. M. et al. The efcacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers. J. Clin. Oncol. 35, abstract LBA2501 (2017).
38. Wahl, R. L., Jacene, H., Kasamon, Y. & Lodge, M. A. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J. Nucl. Med. 50, 122S-150S (2009).
39. Cheng, D. T. et al. Memorial Sloan Kettering-Integrated Mutation Profling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J. Mol. Diagn. 17, 251-264 (2015).
40. Chang, M. T. et al. Accelerating discovery of functional mutant alleles in cancer. Cancer Discov. http://doi.org/10.1158/2159-8290.CD-17-0321 (2017).
41. Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27-30 (2000).
42. Chakravarty D. et al. OncoKB: a precision oncology knowledge base. JCO Precis. Oncol. http://doi.org/10.1200/PO.17.00011 (2017).
43. Shen, R. & Seshan, V. E. FACETS: allele-specifc copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 44, e131 (2016).
44. Carter, S. L. et al. Absolute quantifcation of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413-421 (2012).
45. McGranahan, N. et al. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci. Transl. Med. 7, 283ra54 (2015).
46. Niu, B. et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. Bioinformatics 30, 1015-1016 (2014).
47. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
48. Middha et al. Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data. JCO Precis. Oncol. http://doi. org/10.1200/PO.17.00084 (2017).
49. Zhou, X. et al. Exploring genomic alteration in pediatric cancer using ProteinPaint. Nat. Genet. 48, 4-6 (2016).